focus -WSS

focus

author：explore 2025-09-27 22:50:08 - browse：91

Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going to move markets in 2024?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.

For more on what we cover, here’s the news on Dewpoint Therapeutics; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： What to know about the judge who will handle the Trump case

explore

WSS

BMS, looking to build heart drug business, turns to AI for diagnosis

Cheap, fast test for Zika and dengue could cost just $1

Patients, digital health players weigh in on FTC's data privacy plan

Maui wildfire now ranks as the fifth

Study: Why relieving medical debt did not improve financial outcomes

Cigna wins case to block Amy Bricker's move to CVS

hotspot

focus

Wikipedia

Activists slam private health insurers over coverage restrictions

Cigna wins case to block Amy Bricker's move to CVS

Wildfire smoke exposes gaps in outdoor worker protections

Idaho college killings prosecutors challenge defense's grand jury claims

What does generative AI mean for health care? We asked experts

Maui wildfire now ranks as the fifth

Medicare details structure of new drug price negotiation program

Novo Nordisk touts Wegovy study, but still struggling with supply

Medicare proposal to cover medical devices draws a mixed reaction

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

explore

Idaho college killings prosecutors challenge defense's grand jury claims

Idaho college killings prosecutors challenge defense's grand jury claims

What to know about the judge who will handle the Trump case

Schizophrenia gene found to be linked to cells' energy dysfunction

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Health care court cases: Humana, Sutter, Novant

explore

explore

hotspot

hotspot